mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic

Two decades ago, mRNA became the focus of research in molecular medicine and was proposed as an active pharmaceutical ingredient for the therapy of cancer. In this regard, mRNA has been mainly used for ex vivo modification of antigen-presenting cells (APCs), such as dendritic cells (DCs). This vacci...

Full description

Bibliographic Details
Main Authors:	Van Lint, Sandra, Heirman, Carlo, Thielemans, Kris, Breckpot, Karine
Format:	Online
Language:	English
Published:	Landes Bioscience 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859745/

id	pubmed-3859745
recordtype	oai_dc
spelling	pubmed-38597452013-12-16 mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic Van Lint, Sandra Heirman, Carlo Thielemans, Kris Breckpot, Karine Commentary Two decades ago, mRNA became the focus of research in molecular medicine and was proposed as an active pharmaceutical ingredient for the therapy of cancer. In this regard, mRNA has been mainly used for ex vivo modification of antigen-presenting cells (APCs), such as dendritic cells (DCs). This vaccination strategy has proven to be safe, well tolerated and capable of inducing tumor antigen-specific immune responses. Recently, the direct application of mRNA for in situ modification of APCs, hence immunization was shown to be feasible and at least as effective as DC-based immunization in pre-clinical models. It is believed that application of mRNA as an off-the-shelf vaccine represents an important step in the development of future cancer immunotherapeutic strategies. Here, we will discuss the use of ex vivo mRNA-modified DCs and “naked mRNA” for cancer immunotherapy focusing on parameters such as the employed DC subtype, DC activation stimulus and route of immunization. In addition, we will provide an overview on the clinical trials published so far, trying to link their outcome to the aforementioned parameters. Landes Bioscience 2013-02-01 2013-01-04 /pmc/articles/PMC3859745/ /pubmed/23291946 http://dx.doi.org/10.4161/hv.22661 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Van Lint, Sandra Heirman, Carlo Thielemans, Kris Breckpot, Karine
spellingShingle	Van Lint, Sandra Heirman, Carlo Thielemans, Kris Breckpot, Karine mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
author_facet	Van Lint, Sandra Heirman, Carlo Thielemans, Kris Breckpot, Karine
author_sort	Van Lint, Sandra
title	mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
title_short	mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
title_full	mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
title_fullStr	mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
title_full_unstemmed	mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
title_sort	mrna: from a chemical blueprint for protein production to an off-the-shelf therapeutic
description	Two decades ago, mRNA became the focus of research in molecular medicine and was proposed as an active pharmaceutical ingredient for the therapy of cancer. In this regard, mRNA has been mainly used for ex vivo modification of antigen-presenting cells (APCs), such as dendritic cells (DCs). This vaccination strategy has proven to be safe, well tolerated and capable of inducing tumor antigen-specific immune responses. Recently, the direct application of mRNA for in situ modification of APCs, hence immunization was shown to be feasible and at least as effective as DC-based immunization in pre-clinical models. It is believed that application of mRNA as an off-the-shelf vaccine represents an important step in the development of future cancer immunotherapeutic strategies. Here, we will discuss the use of ex vivo mRNA-modified DCs and “naked mRNA” for cancer immunotherapy focusing on parameters such as the employed DC subtype, DC activation stimulus and route of immunization. In addition, we will provide an overview on the clinical trials published so far, trying to link their outcome to the aforementioned parameters.
publisher	Landes Bioscience
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859745/
_version_	1612037548913197056

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic

Similar Items